开发一种基于J型帕拉米克索病毒的疫苗载体
Elizabeth R Wrobel1, Julia Paton-Smith1, Caroline Piotrowski1
1Department of Infectious Diseases, University of Georgia College of Veterinary Medicine, Athens, GA, USA.
NPJ vaccines
|January 6, 2026
概括
这项研究开发了一种全新的,完全减弱的吉林帕拉米克索病毒 (JPV) 疫苗载体. 这种新的JPV载体在单次鼻内免疫接种后可以保护人免受致命的尼帕病毒挑战.
科学领域:
- 病毒学 病毒学
- 疫苗学 疫苗学 疫苗学
- 分子生物学分子生物学
背景情况:
- 吉林帕拉米克索病毒 (JPV) 是一种负链RNA病毒.
- 再组合JPV (rJPV) 载体对疫苗开发有希望,但可能导致不良影响.
- 为了更安全的疫苗平台,需要进一步减弱rJPV载体.
研究的目的:
- 开发一种完全减弱的基于JPV的疫苗载体.
- 评估修饰的rJPV突变的致病性和免疫性.
- 评估新型载体对尼帕病毒的保护功效.
主要方法:
- 通过删除特定的基因 (SH,SP,X) 生成多个rJPV突变.
- 引入了L基因突变进入rJPV-∆3以创建rJPV-∆3-LW-L.
- 使用尼帕病毒融合 (F) 蛋白表达,对小鼠的致病性和小鼠和仓鼠的免疫性/有效性进行了测试.
主要成果:
- 缺乏SH,SP或SH/SP/X基因的rJPV仍然具有病原性.
- 具有L基因突变的rJPV-∆3 (rJPV-∆3-LW-L) 在小鼠中完全减弱.
- rJPV-∆3-LW-L表达NiV-F诱导了抗NiV-F抗体,并提供了对子致命的NiV挑战的完整保护.
结论:
- 一种新的,完全减弱的鼻内JPV疫苗载体 (rJPV-∆3-LW-L) 成功开发.
- 这种载体表明了对尼帕病毒等病毒病原体进行有效的鼻内免疫的潜力.
- 这些发现支持推进基于rJPV的疫苗平台.
相关概念视频
01:51Vaccinations
Overview
01:22Development of Immunocompetence
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
01:29Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:23Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
01:17Poliomyelitis
Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...